Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1/2 3Phase 1 3Phase NA 1Phase 4 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Leukemia, Myeloid, Acute 25Advanced Solid Tumors 18Breast Neoplasms 12Myelodysplastic Syndromes 11Neoplasms 10Advanced Solid Tumor 10Prostatic Neoplasms 9Solid Tumor 7Neoplasm Metastasis 7Multiple Myeloma 7Recurrence 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Colorectal Neoplasms 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Melanoma 4Leukemia, Myelomonocytic, Chronic 4Leukemia 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Primary Myelofibrosis 2Nasopharyngeal Carcinoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2

Interventions

Radiotherapy 38Carboplatin 37pembrolizumab 36Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Magnetic Resonance Spectroscopy 16Cyclophosphamide 15osimertinib 14Irinotecan 13Etoposide 13Radiation 12Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 8Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × Injections × Clear all
NCT04081688 2026-02-05

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Rutgers, The State University of New Jersey

Phase 1 Terminated
16 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06948539 2025-04-29

To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Not yet recruiting
66 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡